|
Volumn 7, Issue 12, 2011, Pages 659-660
|
Multiple sclerosis: Combination therapy in MS-still a valid strategy
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BETA1A INTERFERON;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
MEVALONIC ACID;
PLACEBO;
SIMVASTATIN;
STAT1 PROTEIN;
STAT2 PROTEIN;
ADD ON THERAPY;
ANTIINFLAMMATORY ACTIVITY;
ARTICLE;
CELL MIGRATION;
DISEASE ACTIVITY;
DRUG ANTAGONISM;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG MEGADOSE;
DRUG RESPONSE;
HUMAN;
HYPERCHOLESTEROLEMIA;
MONOTHERAPY;
MULTIPLE SCLEROSIS;
NONHUMAN;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RECURRENCE RISK;
DRUG THERAPY, COMBINATION;
HUMANS;
HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;
INTERFERON-BETA;
MULTIPLE SCLEROSIS;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
REPRODUCIBILITY OF RESULTS;
|
EID: 83055180753
PISSN: 17594758
EISSN: 17594766
Source Type: Journal
DOI: 10.1038/nrneurol.2011.164 Document Type: Article |
Times cited : (7)
|
References (8)
|